PCM
EWTX icon

Peregrine Capital Management’s Edgewise Therapeutics EWTX Stock Holding History

Peregrine Capital Management’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.07M Sell
198,570
-10,102
-5% -$348K 0.26% 119
2026
Q1 		$6.57M Buy
+208,672
New +$6.02M 0.24% 122

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Peregrine Capital Management's EWTX Position: Q2 2026 in Review

Peregrine Capital Management reduced its Edgewise Therapeutics (EWTX) stake by 4.8% in Q2 2026, selling an estimated $348K and leaving 198,570 shares worth $8.07M. The position accounts for 0.26% of the portfolio, ranked #119.

Peregrine Capital Management first reported a position in EWTX in Q1 2026 and has held it in 2 quarters since. 225 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Peregrine Capital Management held 198,570 shares of Edgewise Therapeutics worth $8.07M as of Q2 2026.
  • Peregrine Capital Management sold 10,102 Edgewise Therapeutics shares in Q2 2026, an estimated $348K.
  • Edgewise Therapeutics made up 0.26% of Peregrine Capital Management's portfolio in Q2 2026, its #119 holding.
  • Peregrine Capital Management first reported a position in Edgewise Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 225 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Peregrine Capital Management's 13F filing for Q2 2026, filed 17 Jul 2026.